 Today, I have the pleasure of speaking with Brent Willis from Voyager Pharmaceuticals. How are you today? I'm doing great. How are you doing? I think we should just hit the ground running here. We enjoyed you on Investor Talk today. And specifically, the most dramatic item you mentioned to our audience was that you recently had a valuation placed on Voyager Pharmaceuticals of $344 million, and yet your market cap is $11 million. Is that correct? Yeah. That's correct. We're just marching through the markets here, and we can't worry too much about our market cap. We just got to focus on our milestones to keep hitting them, so it'll come. And speaking of milestones, you're in a contrast industry, barium, iodine, contrast. Is that correct? That's right. And you were talking about how this industry, similar to the critical materials, many of the critical materials we cover, which is our audience, they love this. China is controlling a lot of these contrast output products like iodine, and it's creating a real fury out there for hospitals not being able to access this. Is that correct? That's right. So in radiology, contrast is used to allow the doctor to detect the disease and tumors and things that are wrong with you inside your body. And if you can't go in and get those scans and those problems get worse, and people are passing away because they can't go in and get their scans done, they're being canceled across North America. And the reason for that is because the majority of iodinated contrast comes out of China, and we have supply chain issues with barium sulfate, and it's a supply chain issue, and it's very foretelling. And when we're looking at our future, when we cannot supply our own hospitals with very much needed drugs, just based on a few port closures in China, so it really highlights the importance of domestic supply and moving forward with domestic production. And of course, I love just Brent as an aside, I love California investors. They go, you know, climate change matters to us, so they went in and became ESG investors, went in, bought and held. So all of us baby boomers and older Gen Xs that are going to be lining up for these types of processes, we may want to invest in helping support you in building the supply chain. And to me, that's what, that sounds credible. Yeah, absolutely. And we have a very marine agenda with our company too, we're, you know, our whole Francis Creek project is very low impact on the environments, we're eliminated in use of water, and we're, we're very environmentally focused in that sense. We have a lot of, a lot of stakeholder with our First Nations support, and, and we're very conscious of ESG and what it means for a company. And let's just talk about barium prices. Did you just, did I hear you correctly saying that barium is gone from 3,800 to $17,000? Is this US, Canadian, and for how much of, how much barium are we talking about? Yeah, we're, we're, we're looking at sourcing. So we're importing USP pharmaceutical grade barium sulfate. And that price has gone up to $17,000 a ton. We're looking at ordering for that. We're going to pay that to bring it in and to ensure that we have our supply chain and tax to move our initial sales off the ground. We have barite on the ground. We do have enough supply to get our production launched. And, but it really puts a focus on how important it is to, to get our Francis Creek project off the ground and moving forward. And we're looking at building a smaller plant, something that we hope will cost less than $2 million and almost like a bench scale processing to do up to three to three or four kilograms an hour. And which with our initial product rollout, we're looking at 300 bottles an hour. And that's enough to generate cash flow in the hundreds of thousands a month once we, we establish our markets. So I think that's going to be our first phase is start small. Low cap X, get our products to market in Canada and keep working with the FDA. We're going to get into the US markets down the road. We're not going to put any timelines on that. We've had very positive meetings with the FDA, but it's hard to put a timeline on their working through regulatory pathways for us to try to figure out how they're going to regulate this, this product that used to be a drug that was recently ruled on to be a device. So there's some issues there that the FDA still needs to work through. Well, Brent, thank you so much for the update. Please next news release. I want you on investor intel immediately. All right. Thank you.